D’Hondt et al Lockhart PB, Brennan MT, Kent ML, et al. 2005. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant, 35:713-20. Lorusso D, Ferrandina G, Greggi S, et al. 2003. Phase III multicenter randomised trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol, 14:1086-93. MacDonald K, Hill G. 2002. Keratinocyte growth factor (KGF) in haematology and oncology. Curr Pharm Des, 8:395-403. Mahood DJ, Dose AM, Loprinzi CL, et al.1991. Inhibition of fluouracil- induced stomatatis by oral cryotherapy. J Clin Oncol, 9:449-52. Makkonen TA, Minn H, Jekunen A, et al. 2000. Granulocyte macrophage- colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomised study. Int J Radiat Oncol Biol Phys, 46:525-34. Mascarin M, Franchin G, Minatel E, et al. 1999. The effect of granulocyte colony- stimulating factor on oral mucositisin head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol, 35:203-8. McManus LM, Ostrom KK, Laer C, et al. 1993. Radiation-induced increased platelet-activating factor activity in mixed saliva. Lab Invest, 68:118-24. [MAC] Meta-Analysis Group in Cancer. 1998. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol, 16:3537-41. Meropol NJ, Somer RA, Gutheil J, et al. 2003. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol, 21:1452-8. Neumann TK, Foote MA. 2003. The development of supportive-care agents for patients with cancer. Biotechn Ann Rev, 9:397-416. Oelmann E, Haghu S, Kulimova E, et al. 2004. Influence of keratinocyte growth factor on clonal growth of epithelial cells, lymphoma and leukaemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro. Int J Oncol, 25:1001-12. Okuno SH, Woodhouse CO, Loprinzi CL, et al. 1999. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol, 22:258-61. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. 2000. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood, 96:4350-6. Panoskaltsis-MortariA, Ingbar DH, Jung P, et al. 2000. KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT. Am J Physiol Lung Cell Mol Physiol, 278:988-99. Peterman A, Cella D, Glandon G, et al. 2001. Mucositis in head and neck cancer : economic and quality-of-life outcomes. J Natl Cancer Inst Monogr, 29:45-51. Peterson DE, Cariello A. 2004. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Sem Oncol, 31:35-44. Peterson D, Beck S, Keefe D. 2004. Novel therapies. Sem Oncol Nursing, 20:53-8. Pitten FA, Kiefer T, Buth C, et al. 2003. Do cancer patients with chemotherapy- induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomised, controlled study. J Hosp Infect, 53:283-91. Popescu RA, Norman A, Ross PJ, et al. 1999. Adjuvant or palliative chemotherapy for colorectal cancerin patients 70 years or older. J Clin Oncol, 17:2412-8. Pytlik R, Benes P, Patorkova M et al. 2002. Standardized parenteral alanyl- glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomised, double-blind placebo controlled study. Bone Marrow Transplant, 30:953-61. Rao Naidu MU, Venkat Ramana G, Usha Rani P, et al. 2004. Chemotherapy- induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia, 6:423-31. Reynolds CM, Levine JE, Uberti JP, et al. 2004. Keratinocyte Growth Factor (Palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host disease (aGvHD) in patients at high risk of a GvHD [abstract]. Blood, 104:1228. Rogers PD, Jenkins JK, Chapman SW, et al. 1998. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis, 178:1726-33. Rubenstein EB, Peterson DE, Schubert M, et al. 2004. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 100:2026-46. Rubin JS, Osada H, Finch PW, et al. 1989. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A, 86:802-6. Saadeh CE. 2005. Chemotherapy and radiotherapy-induced oral mucositis: review of perspective strategies and treatment. Pharmacotherapy, 25:540-54. Sharma R, Tobin P, Clarke SJ. 2005. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol, 6:93-102. Skubitz KM, Anderson PM. 1996. Oral glutamine to prevent chemotherapy induced stomatatis: a pilot study. J Lab Clin Med, 127:223-8. Sonis ST, Elting LS, Keefe D, et al. 2004. Perspectives on cancer therapy- induced mucosal injury. Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 100:1995-2025. Sonis ST. 2004. A biological approach to mucositis. J Support Oncol, 2:21- 36. Sonis ST. 1998. Mucositis as a biologic process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol, 34:39-43. Sonis ST. 2002. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplasic therapy. Crit Rev Oral Biol Med, 13:380-9. Spencer A, Horvath N, Gibson J, et al. 2005. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant, 35:971-7. Spielberger R, Stiff P, Bensinger W, et al. 2004. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med, 351:10-18. Trotti A, Byhardt R, Stetz J, et al. 2000. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys, 47:13-47. Ulrich CM, Yasui Y, Storb R, et al. 2001. Pharmacogenetics of methotrexate toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 98:231-4. Vanclée A, Lutgens LC, Oving EB, et al. 2005. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant, 36:907-15. Wang J, Albertson CM, Zheng H, et al. 2002. Short-term inhibition of ADP- induced platelet aggregation by clopidrogel ameliorates radiation-induced toxicity in rat small intestine. Thromb Haemost, 87:122-8. Wardley AM, Jayson GC, Swindell R, et al. 2000. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and hematopoietic progenitor rescue. Br J Haematol, 110:292-9. Wilkes JD. 1998. Prevention and treatment of oral mucositis following cancer chemotherapy. Sem Oncol, 25:538-51. [WHO] World Health Organization. 1996. Cancer pain relief (2nd ed). Genova, Italy: WHO Wright J, Feld R, Knox J. 2005. Chemotherapy-induced oral mucositis: new approaches to prevention and management. Exp Opin Drug Saf, 4:193- 200. Wymenga AN, van der Graaf WT, Spijkervet FK, et al. 1997. A new in vitro assay of quantitation of chemotherapy induced mucositis. Br J Cancer, 8:1062-6. Wymenga AN, van der Graaf WT, Hofstra LS, et al. 1999. Phase I study of transforming growth factor-beta 3 mouthwashes for prevention of chemotherapy induced mucositis. Clin Cancer Res, 5:1363-8. 168 Therapeutics and Clinical Risk Management 2006:2(2)